ASCO 2025 | Sequencing zolbetuximab in gastroesophageal adenocarcinoma

I think zolbetuximab will be here to stay in a first-line setting and I think that we really need to look at where zolbetuximab will be positioned especially with the CPS scoring that is that is up there with more than one, more than five, more than ten, and I think that it will be here to stay compared to checkpoint inhibition, but I think it will be worthwhile exploring also other biomarkers and patients who progress under that biomarker, whether they can be offered anti-CLDN-directed therapies, for instance, in HER2 populations, should not be excluded after progression under HER2-directed therapy to go into a CLDN-directed therapy of the CLDN-positive. So I’m hoping actually that this trial shows that we can use in all comers CLDN-positive in subsequent treatment lines to be more innovative and do not take into account also MSI population can be CLDN-positive and not all patients respond well to immunotherapy. And the second part that I wanted to discuss is that there is still a subset of patients who are all negative and it’s around 10% in our cohorts and these are the patients with now with the biggest unmet needs, so I think we would need to thoroughly investigate where other drivers could be, maybe potentially there, and if there maybe is a unique subset of patients where other targets could be discovered.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.